Tell us your learning needs |
|
|
|
|
|
|
|
Major Depressive Disorder (MDD)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On a scale of 1 to 4, please rate your current level of knowledge and interest in learning more about each of the following topics.
|
Challenges in MDD diagnosis: e.g. differential diagnosis (BP, ADHD, Borderline Personality etc.) |
|
|
|
|
|
|
|
|
|
|
Management of comorbidities in MDD (ADHD, Borderline Personality etc.) |
|
|
Scales to establish a diagnosis and assess depression severity (e.g., HAM-D, PHQ-9, BDI,
MADRS, etc.) |
|
|
Initiation of antidepressant (AD) (choice of appropriate AD and differentiation between agents) |
|
|
|
Specific features of MDD (e.g. anhedonia, low energy, emotional blunting)
|
|
|
Treatment Decisions (e.g., dose or medication adjustments, switch, adjunctive treatment)
after initial assessment of early treatment response |
|
|
|
|
|
|
|
What educational/learning formats/length do you prefer (select all that apply)?
|
Modules/patient cases |
|
Ask the expert sessions |
|
Podcasts |
|
Expert journal clubs |
|
Post-conference highlights |
|
Small group discussions |
|
Hospital rounds |
|
Symposia (Local) |
|
Symposia (National) |
|
Symposia (International) |
|
Journal articles |
|
|
Self-learning
|
|
|
Migraine
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On a scale of 1 to 4, please rate your current level of knowledge and interest in learning more about each of the following topics.
|
Clinical features of migraine and symptom recognition and
Differentiation of migraine from other types of headache disorders |
|
|
|
|
|
|
|
|
|
|
Neurobiology of migraine |
|
|
Burden of migraine in patients from onset through recovery |
|
|
Migraine and comorbidities-patient management |
|
|
Mechanism(s) of action (MOA) of new and emerging preventive treatments |
|
|
Safety and efficacy data from the clinical trials for CGRP receptor
antagonists in the acute management of migraine |
|
|
|
Evidence-based related to monoclonal antibody therapy and its relevance
in the safe and effective use of antiCGRP monoclonal antibodies (mAbs)
for migraine prevention
|
|
|
|
Safety and tolerability profile:
AntiCGRP monoclonal antibodies
CGRP receptor antagonists
|
|
|
Adherence to long-term migraine preventative treatments |
|
|
Switching between existing and emerging treatments
|
|
|
Combining antiCGRP-mAbs with other prophylactic medications
|
|
|
Updated guidelines on the management of migraine
|
|
|
Diagnosis and management of medication overuse headache
|
|
|
|
|
|
|
|
What educational/learning formats/length do you prefer (select all that apply)?
|
Modules/patient cases |
|
Ask the expert sessions |
|
Podcasts |
|
Expert journal clubs |
|
Post-conference highlights |
|
Small group discussions |
|
Hospital rounds |
|
Symposia (Local) |
|
Symposia (National) |
|
Symposia (International) |
|
Journal articles |
|
|
Self-learning
|
|
|
Schizophrenia
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On a scale of 1 to 4, please rate your current level of knowledge and interest in learning more about each of the following topics.
|
|
|
Current Level of Knowledge
V-Low V-High
|
Desired Level of Knowledge
V-Low V-High
|
Most common challenges you experience when making the diagnosis of schizophrenia
(such as: time required to complete diagnosis, differential diagnosis, assessing comorbidities
[e.g., substance abuse], patient denial/reluctance) |
|
|
|
Tools or resources that could further help you overcome any ongoing challenges
|
|
|
|
Discussion about inititiation of long-acting injectable (LAI) as a potential treatment option
|
|
|
In the inpatient setting, treatment considerations when initating treatment
(such as: clinical experience, medication selection, efficacy and tolerability data,
switch, initiation and adherence to treatment) |
|
|
In the inpatient setting, challenges when initiating an atypical LAI
(such as: clinical experience, medication selection, efficacy and tolerability
data, switch, initiation and adherence to treatment) |
|
|
In the outpatient setting, treatment considerations when initating treatment
(such as: ongoing reduction of positive and negative symptoms, calming
effect/reduction of agitation, long-term maintenance of efficacy and functioning,
minimizing adverse events, HCP-patient shared decision making) |
|
|
In the outpatient setting, challenges when initating oral treatment |
|
|
In the outpatient setting, challenges when initiating an atypical LAIs
(such as: clinical experience, medication selection, efficacy and tolerability
data, switch, initiation and adherence to treatment) |
|
|
Adding as needed (Pro re nata PRN) medications for patients who
require short-term sedation when initiating antipsychotic treatment |
|
|
Patient monitoring for ongoing treatment tolerability and maintenance of efficacy |
|
|
|
|
|
|
|
What educational/learning formats/length do you prefer (select all that apply)?
|
Modules/patient cases |
|
Ask the expert sessions |
|
Podcasts |
|
Expert journal clubs |
|
Post-conference highlights |
|
Small group discussions |
|
Hospital rounds |
|
Symposia (Local) |
|
Symposia (National) |
|
Symposia (International) |
|
Journal articles |
|
|
Self-learning
|
|
|